The Hong Kong Competition Authority clarifies its approach to information exchange in a case involving the pharmaceutical sector (Hong Kong Association of the Pharmaceutical Industry)

This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards.

The Hong Kong Competition Commission (“HKCC”) recently published its decision relating to a proposed market sales survey by the Hong Kong Association of the Pharmaceutical Industry (“HKAPI”). The HKCC concluded that the proposed survey is not excluded from the prohibition against anticompetitive arrangements as it was unlikely to generate sufficient efficiencies to the benefit of consumers. This is the first decision by the HKCC under section 11 of the Ordinance relating to economic efficiencies. As well as demonstrating the HKCC’s ability to swiftly review proposed conduct, the decision gives much welcomed and deeper insight into a yet untested area of the law. HKCC’s Decision - would the proposed survey generate economic efficiencies? The HKAPI is an association representing the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Linklaters (Hong Kong)
  • Linklaters (Hong Kong)

Quotation

Marcus Pollard, Kathleen Gooi, The Hong Kong Competition Authority clarifies its approach to information exchange in a case involving the pharmaceutical sector (Hong Kong Association of the Pharmaceutical Industry), 22 October 2019, e-Competitions Hong Kong Competition Law, Art. N° 96936

Visites 46

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues